CN104169258B - 用作激酶活性调节剂的新颖的杂环羧酰胺 - Google Patents
用作激酶活性调节剂的新颖的杂环羧酰胺 Download PDFInfo
- Publication number
- CN104169258B CN104169258B CN201280063286.7A CN201280063286A CN104169258B CN 104169258 B CN104169258 B CN 104169258B CN 201280063286 A CN201280063286 A CN 201280063286A CN 104169258 B CN104169258 B CN 104169258B
- Authority
- CN
- China
- Prior art keywords
- hal
- quinazoline
- replaced
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(C(C1)C1*1C#*)C1=C Chemical compound CC(C(C1)C1*1C#*)C1=C 0.000 description 5
- PIRVXKLBTOWDPF-UHFFFAOYSA-N CCC(C(C(CC1)(CN1c(cc1)c(cncn2)c2c1C(N)=O)N=C)=O)c1ccccc1 Chemical compound CCC(C(C(CC1)(CN1c(cc1)c(cncn2)c2c1C(N)=O)N=C)=O)c1ccccc1 PIRVXKLBTOWDPF-UHFFFAOYSA-N 0.000 description 1
- SEEPOQRQNVNTRO-UHFFFAOYSA-N Cc(ccc(Cl)c1)c1N(CC1)CCN1C(C1=CCN=CN=C1C1)=CC=C1C(N=N)O Chemical compound Cc(ccc(Cl)c1)c1N(CC1)CCN1C(C1=CCN=CN=C1C1)=CC=C1C(N=N)O SEEPOQRQNVNTRO-UHFFFAOYSA-N 0.000 description 1
- CZZPTQNISBIQOI-UHFFFAOYSA-N NC(c(cc1)c2ncccc2c1NCc1cccc(F)c1)O Chemical compound NC(c(cc1)c2ncccc2c1NCc1cccc(F)c1)O CZZPTQNISBIQOI-UHFFFAOYSA-N 0.000 description 1
- ARDCHIOWMUVWOX-XPCCGILXSA-N NC(c(cc1)c2ncncc2c1NC(CNC1)[C@H]1c1cc(F)cc(Cl)c1)=O Chemical compound NC(c(cc1)c2ncncc2c1NC(CNC1)[C@H]1c1cc(F)cc(Cl)c1)=O ARDCHIOWMUVWOX-XPCCGILXSA-N 0.000 description 1
- XMDIFFNNRQWCSJ-UHFFFAOYSA-N NC1OC1c(cc1)c2ncccc2c1NCc(cc1)cc(F)c1F Chemical compound NC1OC1c(cc1)c2ncccc2c1NCc(cc1)cc(F)c1F XMDIFFNNRQWCSJ-UHFFFAOYSA-N 0.000 description 1
- YXCWXBIECMWDNI-UHFFFAOYSA-N O=C(C1(CNC(OCc2ccccc2)=O)CNCCC1)Nc1ccccc1 Chemical compound O=C(C1(CNC(OCc2ccccc2)=O)CNCCC1)Nc1ccccc1 YXCWXBIECMWDNI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579377P | 2011-12-22 | 2011-12-22 | |
| US61/579,377 | 2011-12-22 | ||
| PCT/US2012/070085 WO2013096194A1 (en) | 2011-12-22 | 2012-12-17 | Novel heterocyclic carboxamides as modulators of kinase activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104169258A CN104169258A (zh) | 2014-11-26 |
| CN104169258B true CN104169258B (zh) | 2017-03-01 |
Family
ID=47459185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280063286.7A Expired - Fee Related CN104169258B (zh) | 2011-12-22 | 2012-12-17 | 用作激酶活性调节剂的新颖的杂环羧酰胺 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9139568B2 (enExample) |
| EP (1) | EP2794571B1 (enExample) |
| JP (2) | JP6193880B2 (enExample) |
| KR (1) | KR102098358B1 (enExample) |
| CN (1) | CN104169258B (enExample) |
| AU (2) | AU2012355494B2 (enExample) |
| BR (1) | BR112014015327B1 (enExample) |
| CA (1) | CA2856448C (enExample) |
| DK (1) | DK2794571T3 (enExample) |
| EA (2) | EA027968B1 (enExample) |
| ES (1) | ES2614232T3 (enExample) |
| HR (1) | HRP20170099T1 (enExample) |
| HU (1) | HUE032918T2 (enExample) |
| IL (1) | IL233199B (enExample) |
| LT (1) | LT2794571T (enExample) |
| MX (1) | MX353062B (enExample) |
| PL (1) | PL2794571T3 (enExample) |
| PT (1) | PT2794571T (enExample) |
| RS (1) | RS55621B1 (enExample) |
| SG (2) | SG11201402387WA (enExample) |
| SI (1) | SI2794571T1 (enExample) |
| WO (1) | WO2013096194A1 (enExample) |
| ZA (1) | ZA201403517B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011282684B2 (en) | 2010-07-29 | 2015-05-21 | Merck Patent Gmbh | Cyclic amine azaheterocyclic carboxamides |
| EA027968B1 (ru) * | 2011-12-22 | 2017-09-29 | Мерк Патент Гмбх | Гетероциклические карбоксамиды в качестве модуляторов активности киназ |
| AR095202A1 (es) * | 2013-03-11 | 2015-09-30 | Merck Patent Gmbh | Heterociclos como moduladores de la actividad quinasa |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| CN115073369A (zh) * | 2022-05-31 | 2022-09-20 | 汉瑞药业(荆门)有限公司 | 一种5-溴喹啉-8-甲醛的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0308897A1 (en) * | 1987-09-24 | 1989-03-29 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO2010093419A1 (en) * | 2009-02-11 | 2010-08-19 | Merck Patent Gmbh | Novel amino azaheterocyclic carboxamides |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1465651A (en) * | 1974-04-19 | 1977-02-23 | Wyeth John & Brother Ltd | Carbocyclic-fused ring pyridine derivatives |
| JPH01156960A (ja) * | 1987-09-24 | 1989-06-20 | Ss Pharmaceut Co Ltd | キノリン誘導体 |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| TW200407324A (en) * | 2002-05-17 | 2004-05-16 | Bristol Myers Squibb Co | Bicyclic modulators of androgen receptor function |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| EP1670771A4 (en) | 2003-09-30 | 2010-09-01 | Irm Llc | COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES |
| WO2005039506A2 (en) | 2003-10-24 | 2005-05-06 | Exelixis, Inc. | P70s6 kinase modulators and method of use |
| PT1687305E (pt) | 2003-11-21 | 2008-10-17 | Novartis Ag | Derivados de 1h-imidazoquinolina como inibidores de proteína quinase |
| ATE447957T1 (de) | 2003-12-09 | 2009-11-15 | Us Gov Health & Human Serv | Verfahren zur unterdrückung einer immunantwort oder zur behandlung von proliferativen erkrankungen |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| JP5274842B2 (ja) | 2004-12-28 | 2013-08-28 | エグゼリクシス， インコーポレイテッド | 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物 |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| EA027968B1 (ru) * | 2011-12-22 | 2017-09-29 | Мерк Патент Гмбх | Гетероциклические карбоксамиды в качестве модуляторов активности киназ |
| ES2670550T3 (es) * | 2013-10-14 | 2018-05-30 | Eisai R&D Management Co., Ltd. | Derivados de quinolina selectivamente sustituidos |
| SG10202103278TA (en) * | 2013-10-14 | 2021-04-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
-
2012
- 2012-12-17 EA EA201400736A patent/EA027968B1/ru not_active IP Right Cessation
- 2012-12-17 HU HUE12808640A patent/HUE032918T2/hu unknown
- 2012-12-17 JP JP2014549176A patent/JP6193880B2/ja not_active Expired - Fee Related
- 2012-12-17 HR HRP20170099TT patent/HRP20170099T1/hr unknown
- 2012-12-17 WO PCT/US2012/070085 patent/WO2013096194A1/en not_active Ceased
- 2012-12-17 US US14/359,937 patent/US9139568B2/en not_active Expired - Fee Related
- 2012-12-17 SI SI201230854A patent/SI2794571T1/sl unknown
- 2012-12-17 KR KR1020147017395A patent/KR102098358B1/ko not_active Expired - Fee Related
- 2012-12-17 RS RS20170071A patent/RS55621B1/sr unknown
- 2012-12-17 CN CN201280063286.7A patent/CN104169258B/zh not_active Expired - Fee Related
- 2012-12-17 AU AU2012355494A patent/AU2012355494B2/en not_active Ceased
- 2012-12-17 DK DK12808640.2T patent/DK2794571T3/en active
- 2012-12-17 EA EA201791073A patent/EA201791073A1/ru unknown
- 2012-12-17 BR BR112014015327-2A patent/BR112014015327B1/pt not_active IP Right Cessation
- 2012-12-17 EP EP12808640.2A patent/EP2794571B1/en active Active
- 2012-12-17 LT LTEP12808640.2T patent/LT2794571T/lt unknown
- 2012-12-17 SG SG11201402387WA patent/SG11201402387WA/en unknown
- 2012-12-17 CA CA2856448A patent/CA2856448C/en active Active
- 2012-12-17 SG SG10201604799TA patent/SG10201604799TA/en unknown
- 2012-12-17 ES ES12808640.2T patent/ES2614232T3/es active Active
- 2012-12-17 PT PT128086402T patent/PT2794571T/pt unknown
- 2012-12-17 PL PL12808640T patent/PL2794571T3/pl unknown
- 2012-12-17 MX MX2014007364A patent/MX353062B/es active IP Right Grant
-
2014
- 2014-05-15 ZA ZA2014/03517A patent/ZA201403517B/en unknown
- 2014-06-17 IL IL233199A patent/IL233199B/en active IP Right Grant
-
2015
- 2015-09-08 US US14/847,561 patent/US20160058763A1/en not_active Abandoned
-
2016
- 2016-08-03 US US15/227,017 patent/US10080753B2/en active Active
-
2017
- 2017-08-10 JP JP2017155667A patent/JP6553686B2/ja not_active Expired - Fee Related
- 2017-10-06 AU AU2017239625A patent/AU2017239625B2/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0308897A1 (en) * | 1987-09-24 | 1989-03-29 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO2010093419A1 (en) * | 2009-02-11 | 2010-08-19 | Merck Patent Gmbh | Novel amino azaheterocyclic carboxamides |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2806610C (en) | Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k | |
| KR101945061B1 (ko) | 시클릭 아민 아자헤테로시클릭 카르복사미드 | |
| AU2017239625B2 (en) | Novel heterocyclic carboxamides as modulators of kinase activity | |
| HK1201829B (en) | Novel heterocyclic carboxamides as modulators of kinase activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1201829 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1201829 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170301 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |